Q-omics provides the consensus-scored C15orf48 profile across patient tissues and cancer cell-line models. C15orf48 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, C15orf48 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, C15orf48 protein abundance shows 15,435 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where C15orf48 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C15orf48 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C15orf48 survival associations across molecular data types. C15orf48 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C15orf48 RNA expression–survival associations across cancer types. High C15orf48 expression shows unfavorable associations in LGG, ESCA and ACC, but favorable associations in SKCM, KIRC and DLBC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for C15orf48 RNA expression.
This table summarizes C15orf48 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for C15orf48. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C15orf48 shows lower tumor expression in COAD and HNSC and higher tumor expression in KIRC, BLCA, LUAD and BRCA. The KIRC box plot shows higher C15orf48 RNA expression in tumor versus normal tissue (log2 FC = +1.357, t-test p < 0.001).
This table shows molecular features associated with C15orf48 in patient tissues and cancer cell lines. In patient samples, C15orf48 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, C15orf48 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_SCLC.
